Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00954174 · OUTCOME

Duration of Progression-free Survival

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer · Source last updated 2021-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Approximately 9 years and 7 months

What was measured

Measured in months from randomization to last contact or the earlier of the date of progression or death.

Analysis population: All eligible patients

Groups in this outcome

Regimen I - Uterine Carcinsarcoma Subjects

Paclitaxel 175 mg/m2 IV over 3 hours Day 1. Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles

Regimen II - Uterine Carcinsarcoma Subjects

Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6

Regimen III - Non-uterine Carcinsarcoma Subjects

Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles

Regimen IV - Non-uterine Carcinsarcoma Subjects

Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen I - Uterine Carcinsarcoma Subjects228
Regimen II - Uterine Carcinsarcoma Subjects221
Regimen III - Non-uterine Carcinsarcoma Subjects44
Regimen IV - Non-uterine Carcinsarcoma Subjects46

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen I - Uterine Carcinsarcoma Subjects16.3Not reported13.018.9Not reported
Regimen II - Uterine Carcinsarcoma Subjects11.7Not reported10.117.3Not reported
Regimen III - Non-uterine Carcinsarcoma Subjects14.6Not reported8.116.4Not reported
Regimen IV - Non-uterine Carcinsarcoma Subjects10.3Not reported8.519.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        13.0
        upper Limit
        18.9
        value
        16.3
      2. group Id
        OG001
        lower Limit
        10.1
        upper Limit
        17.3
        value
        11.7
      3. group Id
        OG002
        lower Limit
        8.1
        upper Limit
        16.4
        value
        14.6
      4. group Id
        OG003
        lower Limit
        8.5
        upper Limit
        19.0
        value
        10.3
denoms
  1. counts
    1. group Id
      OG000
      value
      228
    2. group Id
      OG001
      value
      221
    3. group Id
      OG002
      value
      44
    4. group Id
      OG003
      value
      46
    units
    Participants
description
Measured in months from randomization to last contact or the earlier of the date of progression or death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Paclitaxel 175 mg/m2 IV over 3 hours Day 1. Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles
    id
    OG000
    title
    Regimen I - Uterine Carcinsarcoma Subjects
  2. description
    Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6
    id
    OG001
    title
    Regimen II - Uterine Carcinsarcoma Subjects
  3. description
    Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles
    id
    OG002
    title
    Regimen III - Non-uterine Carcinsarcoma Subjects
  4. description
    Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6
    id
    OG003
    title
    Regimen IV - Non-uterine Carcinsarcoma Subjects
param Type
MEDIAN
population Description
All eligible patients
reporting Status
POSTED
time Frame
Approximately 9 years and 7 months
title
Duration of Progression-free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice